Cooper Companies (NASDAQ:COO) Director Paul Keel Purchases 4,701 Shares

The Cooper Companies, Inc. (NASDAQ:COO) Director Paul Keel bought 4,701 shares of the stock in a transaction dated Friday, September 11th. The stock was purchased at an average cost of $53.18 per share, for a total transaction of $249,999.18. Following the acquisition, the director owned 4,701 shares of the company’s stock, valued at approximately $249,999.18. This represents a ? increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Cooper Companies Stock Performance

Shares of Cooper Companies stock traded down $0.95 on Tuesday, reaching $53.27. 4,408,999 shares of the stock were exchanged, compared to its average volume of 2,501,526. The firm has a market capitalization of $10.13 billion, a PE ratio of 18.18, a PEG ratio of 2.19 and a beta of 0.82. The Cooper Companies, Inc. has a 1-year low of $51.01 and a 1-year high of $89.83. The business has a fifty day moving average price of $71.25 and a two-hundred day moving average price of $69.40. The company has a current ratio of 1.22, a quick ratio of 0.73 and a debt-to-equity ratio of 0.23.

Cooper Companies (NASDAQ:COO) last announced its quarterly earnings data on Wednesday, September 9th. The medical device company reported $1.15 EPS for the quarter, beating analysts’ consensus estimates of $1.12 by $0.03. Cooper Companies had a net margin of 13.46% and a return on equity of 10.90%. The firm had revenue of $1.07 billion during the quarter, compared to the consensus estimate of $1.10 billion. During the same quarter last year, the firm earned $0.49 earnings per share. The firm’s revenue was up .5% compared to the same quarter last year. Cooper Companies has set its Q4 2026 guidance at 1.050-1.090 EPS and its FY 2026 guidance at 4.510-4.550 EPS. As a group, research analysts anticipate that The Cooper Companies, Inc. will post 4.53 earnings per share for the current fiscal year.

Cooper Companies announced that its board has approved a stock repurchase plan on Wednesday, September 9th that allows the company to repurchase $3.00 billion in shares. This repurchase authorization allows the medical device company to repurchase up to 22.7% of its shares through open market purchases. Shares repurchase plans are generally a sign that the company’s board of directors believes its shares are undervalued.

Analyst Upgrades and Downgrades

COO has been the topic of a number of recent analyst reports. Wall Street Zen lowered Cooper Companies from a “buy” rating to a “hold” rating in a report on Saturday. Mizuho set a $75.00 target price on Cooper Companies and gave the company an “outperform” rating in a report on Thursday, September 10th. Wells Fargo & Company set a $61.00 target price on shares of Cooper Companies and gave the stock an “equal weight” rating in a research report on Thursday, September 10th. Zacks Research cut shares of Cooper Companies from a “hold” rating to a “strong sell” rating in a research note on Friday. Finally, Weiss Ratings reiterated a “sell (d)” rating on shares of Cooper Companies in a report on Friday, September 4th. Five equities research analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and three have issued a Sell rating to the company. According to MarketBeat.com, Cooper Companies has an average rating of “Hold” and a consensus target price of $71.47.

Institutional Investors Weigh In On Cooper Companies

Institutional investors and hedge funds have recently modified their holdings of the company. BlackRock Inc. purchased a new stake in Cooper Companies during the second quarter worth $1,077,762,000. Generation Investment Management LLP acquired a new stake in Cooper Companies in the second quarter valued at $356,304,000. Jupiter Topco LLC purchased a new position in shares of Cooper Companies in the second quarter valued at $305,074,000. Franklin Resources Inc. increased its position in shares of Cooper Companies by 108.2% in the fourth quarter. Franklin Resources Inc. now owns 4,022,033 shares of the medical device company’s stock valued at $329,646,000 after buying an additional 2,089,763 shares in the last quarter. Finally, JANA Partners Management LP raised its stake in shares of Cooper Companies by 0.5% during the 2nd quarter. JANA Partners Management LP now owns 3,582,480 shares of the medical device company’s stock worth $256,900,000 after buying an additional 17,322 shares during the last quarter. Institutional investors and hedge funds own 24.39% of the company’s stock.

Cooper Companies Company Profile

Cooper Companies, Inc is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company develops, manufactures and markets products through two primary business segments: CooperVision and CooperSurgical.

CooperVision specializes in contact lenses, including daily disposable, toric, multifocal, multifocal toric, specialty and myopia-management lenses. Its products are designed to address a range of vision-correction needs, including astigmatism, presbyopia and irregular corneas.